Jiang Wei, a major shareholder and controller of Shanghai Haohai Biological Technology, has received a decision on bail pending trial from the Shanghai Public Security Bureau for alleged insider trading. This follows a previous administrative penalty from the China Securities Regulatory Commission in December 2025 for similar offenses. The company has stated that this matter is unrelated to Haohai Biological Technology and will not affect its daily operations, as Jiang Wei does not hold a position within the company. AI
Summary written by gemini-2.5-flash-lite from 1 source. How we write summaries →
RANK_REASON The news concerns a legal issue with a company's shareholder, not a core AI development or industry trend.